eXIthera Pharmaceuticals

About:

ExIthera Pharmaceuticals supports the creation of antithrombotic and stroke prevention medications.

Website: http://www.exithera.com

Top Investors: Schooner Capital, Access BridgeGap Ventures

Description:

ExIthera Pharmaceuticals is a developer of an early-stage biotechnology platform used to develop small-molecule pharmaceuticals. The company's stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. It focuses on developing stroke prevention and anti-thrombosis drugs based on Factor XI, which has a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat serious consequences, including venous thromboembolism, deep vein thrombosis, stroke, and heart attack.

Total Funding Amount:

$18M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Westborough, Massachusetts, United States

Founded Date:

2012-01-01

Contact Email:

info(AT)exithera.com

Founders:

Neil J. Hayward

Number of Employees:

1-10

Last Funding Date:

2017-08-10

IPO Status:

Private

Industries:

© 2025 bioDAO.ai